Ricci K. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Four on November 6, 2003, Washington, DC:190.

Roquemore J. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Four on November 6, 2003, Washington, DC: 241-242.


Salinsky E. 2002. Will the Nation Be ready for the Next Bioterrorism Attack? Mending Gaps in the Public Health Infrastructure. NHPF Issue Brief No. 776. Washington, DC: National Health Policy Forum.

Selecky M. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Three on May 1, 2003, Washington, DC:93-94.

Schulman R. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Four on November 6, 2003, Washington, DC:213-214.


Temte J. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Four on November 6, 2003, Washington, DC: 157-159, 165-166, 173-174, 186.

Trimble M. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Four on November 6, 2003, Washington, DC.


White House. 2002. President Delivers Remarks on Smallpox. [Online] Available at http://www.whitehouse.gov/news/releases/2002/12/20021213-7.html. Accessed January 8, 2003.

WHO (World Health Organization). 2003. Unpublished. Strengthening National Health Preparedness and Response for Chemical and Biological Weapons Threats.

Williamson D. 2003. Transcript from the IOM’s Committee on Smallpox Vaccination Program Implementation Meeting Four on November 6, 2003, Washington, DC:109-151.

APPENDIX 5-A DRAFT SMALLPOX INDICATORS AND SUGGESTED CRITERIA

The committee reviewed the draft 10 smallpox indicators included in CDC’s readiness indicators document. The committee’s analysis does not reflect an endorsement of the current indicators as indicative of readiness for smallpox attack. In fact, some of the indicators seem narrow and unclear, whereas others seem to incorporate multiple activities, and it is not evident whether and how they could represent a carefully selected, concise set of the most relevant measures of smallpox preparedness.

The committee outlined four scenarios, discussed the indicators as they would operate in each scenario, and developed some examples of criteria that might help assess a jurisdiction’s work in an area summarized by a given indicator. Unless otherwise noted, the committee believes that the criteria it developed would apply to all scenarios. The committee has also indicated, as appropriate, whether a criterion is applicable to state public health agencies, local public health agencies, or both.

Indicator 1.1.9.1: Legal issues related to smallpox vaccination (e.g., liability, compensation, licensure for administration of vaccine, investigational new drug issues) have been reviewed and addressed.

This indicator should be broadened to more fully reflect the wide range of legal issues pertaining not only to vaccination, but to smallpox prepared-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement